Vigabatrin is a highly effective adjunctive treatment for adults with refractory epilepsy and for infantile spasms. After gaining its license in Europe in 1989, it was used widely with much success until 1997 when reports of permanent visual fields defects were observed in some patients. The use of Vigabatrin had fallen in Europe since, where significant number of patients were denied this treatment leading to inadequate seizure control, poorer quality of life and greater risk of death and injury. In the US, Vigabatrin was made available for their patients in 2009 involving costly and extensive monitoring programme of visual function. The result of long-term monitoring is varied, partly due to the mixed methods used for examination of visua...
Background The antiepileptic drug vigabatrin is associated with characteristic visual field loss (VA...
Vigabatrin is an antiepileptic drug that is known to cause visual field defects and retinal dysfunct...
Background: To report the results of repeated electrophysiological and visual field examinations in ...
Vigabatrin, a GABA (γ-aminobutyric acid) agonist is a drug widely prescribed in Europe and Asia betw...
The purpose of this thesis was to investigate visual dysfunction arising from vigabatrin (VGB) toxic...
The purpose of this thesis was to assess long-term outcomes of the visual dysfunction arising from t...
Background: Use of the antiepileptic drug vigabatrin is associated with an elevated risk of visual f...
Vigabatrin was introduced as an anti-seizure medication in the United Kingdom in 1989 and was extens...
This thesis considers the visual electrophysiological effects of vigabatrin (an anti-epileptic drug,...
Article abstract—Objective: To assess early visual impairment related to vigabatrin prospectively in...
Purpose: To investigate the clinical value of assessment of peripapillary retinal nerve fibre layer ...
SummaryPurposeVigabatrin-associated visual field loss (VAVFL) occurs in around 45% of exposed people...
PURPOSE: The risk factors for visual field loss attributable to vigabatrin (VAVFL) are equivocal. Th...
Objective: To assess the wide-field multifocal electroretinogram (WF-mfERG) for assessment of retina...
OBJECTIVE: Vigabatrin-associated visual field loss (VAVFL) occurs in 25 to 50% of exposed patients a...
Background The antiepileptic drug vigabatrin is associated with characteristic visual field loss (VA...
Vigabatrin is an antiepileptic drug that is known to cause visual field defects and retinal dysfunct...
Background: To report the results of repeated electrophysiological and visual field examinations in ...
Vigabatrin, a GABA (γ-aminobutyric acid) agonist is a drug widely prescribed in Europe and Asia betw...
The purpose of this thesis was to investigate visual dysfunction arising from vigabatrin (VGB) toxic...
The purpose of this thesis was to assess long-term outcomes of the visual dysfunction arising from t...
Background: Use of the antiepileptic drug vigabatrin is associated with an elevated risk of visual f...
Vigabatrin was introduced as an anti-seizure medication in the United Kingdom in 1989 and was extens...
This thesis considers the visual electrophysiological effects of vigabatrin (an anti-epileptic drug,...
Article abstract—Objective: To assess early visual impairment related to vigabatrin prospectively in...
Purpose: To investigate the clinical value of assessment of peripapillary retinal nerve fibre layer ...
SummaryPurposeVigabatrin-associated visual field loss (VAVFL) occurs in around 45% of exposed people...
PURPOSE: The risk factors for visual field loss attributable to vigabatrin (VAVFL) are equivocal. Th...
Objective: To assess the wide-field multifocal electroretinogram (WF-mfERG) for assessment of retina...
OBJECTIVE: Vigabatrin-associated visual field loss (VAVFL) occurs in 25 to 50% of exposed patients a...
Background The antiepileptic drug vigabatrin is associated with characteristic visual field loss (VA...
Vigabatrin is an antiepileptic drug that is known to cause visual field defects and retinal dysfunct...
Background: To report the results of repeated electrophysiological and visual field examinations in ...